Longitudinal Hydrogen–Methane Breath Testing for Suspected Small Intestinal Bacterial Overgrowth and Intestinal Methanogen Overgrowth: Patient-Level Associations and Repeat-Test Outcomes

Background/Objectives: Hydrogen–methane breath testing is widely used for suspected small intestinal bacterial overgrowth (SIBO) and intestinal methanogen overgrowth (IMO), but longitudinal test behavior is poorly characterized. We quantified laboratory normalization at first repeat testing and examined whether index-test hydrogen magnitude was associated with subsequent laboratory status. Methods: This retrospective cohort included breath tests with simultaneous hydrogen and methane measurement performed during 2022–2025. The earliest valid test was the index test. Hydrogen (H2) positivity was defined as a >20-ppm rise above baseline and methane (CH4) positivity according to the historical institutional laboratory operational definition as a >10-ppm rise above baseline; this definition is distinct from conventional IMO classification based on absolute CH4 ≥ 10 ppm. Multivariable logistic regression assessed associations with index positivity and positive-to-negative conversion. All patients with a positive index test who underwent repeat testing reported completing first-line rifaximin before retesting. Results: Among 3082 patients (3446 valid tests), index-test positivity was 48.2%. Increasing age was associated with lower overall positivity (adjusted odd ratio (OR) per 10 years 0.904, 95% confidence interval (CI) 0.871–0.938; p < 0.001), driven by H2 rather than CH4. Of 1487 patients with a positive index test, 279 (18.8%) underwent repeat testing, and 96/279 (34.4%) showed laboratory normalization. Among 262 patients with H2-positive index tests, each 10-ppm increase in index-test hydrogen rise (ΔH2) was associated with lower odds of normalization (adjusted OR 0.844, 95% CI 0.757–0.940; p = 0.002). Conclusions: Among selected patients with a positive index test undergoing post-treatment repeat testing, approximately one-third showed laboratory normalization. Greater index-test ΔH2 was associated with lower odds of normalization within the group of patients with H2-positive index tests. These findings do not establish a validated clinical prediction tool.

Authors

Institutions

Publication Details

Journal
Journal of Clinical Medicine
Published
2026-11-18
DOI
https://doi.org/10.3390/jcm15229056
Primary Topic
Gastrointestinal motility and disorders
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Longitudinal Hydrogen–Methane Breath Testing for Suspected Small Intestinal Bacterial Overgrowth and Intestinal Methanogen Overgrowth: Patient-Level Associations and Repeat-Test Outcomes

Tsachi Tsadok Perets, Yair Huta, Olga Ashorov, Rana Taha et al.
1 links
Journal of Clinical Medicine
Gastrointestinal motility and disorders
article

Longitudinal Hydrogen–Methane Breath Testing for Suspected Small Intestinal Bacterial Overgrowth and Intestinal Methanogen Overgrowth: Patient-Level Associations and Repeat-Test Outcomes

Tsachi Tsadok Perets, Yair Huta, Olga Ashorov, Rana Taha, Dana Ledawi, Meital Izhakov
article en

Abstract

Background/Objectives: Hydrogen–methane breath testing is widely used for suspected small intestinal bacterial overgrowth (SIBO) and intestinal methanogen overgrowth (IMO), but longitudinal test behavior is poorly characterized. We quantified laboratory normalization at first repeat testing and examined whether index-test hydrogen magnitude was associated with subsequent laboratory status. Methods: This retrospective cohort included breath tests with simultaneous hydrogen and methane measurement performed during 2022–2025. The earliest valid test was the index test. Hydrogen (H2) positivity was defined as a >20-ppm rise above baseline and methane (CH4) positivity according to the historical institutional laboratory operational definition as a >10-ppm rise above baseline; this definition is distinct from conventional IMO classification based on absolute CH4 ≥ 10 ppm. Multivariable logistic regression assessed associations with index positivity and positive-to-negative conversion. All patients with a positive index test who underwent repeat testing reported completing first-line rifaximin before retesting. Results: Among 3082 patients (3446 valid tests), index-test positivity was 48.2%. Increasing age was associated with lower overall positivity (adjusted odd ratio (OR) per 10 years 0.904, 95% confidence interval (CI) 0.871–0.938; p < 0.001), driven by H2 rather than CH4. Of 1487 patients with a positive index test, 279 (18.8%) underwent repeat testing, and 96/279 (34.4%) showed laboratory normalization. Among 262 patients with H2-positive index tests, each 10-ppm increase in index-test hydrogen rise (ΔH2) was associated with lower odds of normalization (adjusted OR 0.844, 95% CI 0.757–0.940; p = 0.002). Conclusions: Among selected patients with a positive index test undergoing post-treatment repeat testing, approximately one-third showed laboratory normalization. Greater index-test ΔH2 was associated with lower odds of normalization within the group of patients with H2-positive index tests. These findings do not establish a validated clinical prediction tool.

Journal of Clinical MedicineVol. 15(22)
Holon Institute of Technology (IL), Rabin Medical Center (IL)
Good health and well-being
Gastrointestinal motility and disorders
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon